Eugene Hutchinson

Aug 7, 2024 | jdsupra.com | Kevin Adam |Eugene Hutchinson |Cansu Gunel

August 7, 2024 Kevin Adam, Cansu Gunel, Eugene Hutchinson, Constantin Nuernberger White & Case LLP + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The FTC and private litigants are testing the limits of...

Aug 30, 2023 | jdsupra.com | Kevin Adam |Eugene Hutchinson |Constantin Nuernberger

While only slightly past the midway point of 2023, it has already been a busy year for developments in drug pricing. Notably, CMS released its final guidance in preparation for price negotiations and the first 10 drugs covered under the IRA, constitutional challenges to the IRA's drug-pricing provisions are mounting, and Congress is considering several new bills that seek to ban specific PBM practices and target certain types of conduct by drug manufacturers.

Aug 29, 2023 | lexology.com | Kevin Adam |Eugene Hutchinson |Constantin Nuernberger

While only slightly past the midway point of 2023, it has already been a busy year for developments in drug pricing. Notably, CMS released its final guidance in preparation for price negotiations and the first 10 drugs covered under the IRA, constitutional challenges to the IRA's drug-pricing provisions are mounting, and Congress is considering several new bills that seek to ban specific PBM practices and target certain types of conduct by drug manufacturers.